Sector News

Astellas dives into immuno-oncology with a sweeping biotech deal

April 22, 2015
Life sciences
Japanese pharma giant Astellas is entering the booming field of immuno-oncology, pairing up with Cambridge, MA’s Potenza Therapeutics to work on a wide variety of treatments that use the body’s natural defenses to combat cancer.
 
Under the agreement, Potenza will take the lead on drug discovery with a broad approach to immunotherapy, spotlighting candidates could unblind the immune system to the spread of tumors. Astellas will handle all clinical development thereafter, handing over an undisclosed upfront payment and making an equity investment in the biotech. The drugmaker is also promising future milestone cash tied to ongoing development, and it has picked up the rights to acquire its partner down the road.
 
Astellas, which markets the blockbuster cancer treatment Xtandi, is edging its way into a fast-moving field that promises to change the standard of care for a host of cancers. Companies including Merck, Bristol-Myers Squibb and Roche have already charted major success with antibodies targeting PD-1, PD-L1, CTLA-4 and other targets, but Astellas believes immuno-oncology’s best days are yet ahead.
 
Now, with Potenza in tow, the company hopes it can play a lead role in the second wave of immunotherapies for cancer, looking for novel mechanisms of action to improve upon what’s already in place.
 
“We are at the beginning of a new era in cancer therapy,” Potenza CEO Daniel Hicklin said in a statement. “First-generation immuno-oncology therapeutics have demonstrated meaningful clinical benefit to patients with certain cancers. The new targets and pathways that Potenza is working on offer promise for continued expansion of immunotherapy treatment options.”
 
Astellas played a part in the $38 million A round Potenza closed late last year, joining founding investor MPM Capital and InterWest Partners. Established last year, the biotech has disclosed very little about its proprietary technology, saying only that it is focused on disrupting the mechanisms cancer cells use to evade detection. Potenza’s management team includes veterans of Merck’s oncology division, Millennium Pharmaceuticals and the Novartis ($NVS)-acquired CoStim Pharmaceuticals.
 
By Damian Garde
 
 

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.